Single dose PRO140 mAb reduces viral load by 0.5 log copies/mL in people with multidrug resistance

EMA approves dolutegravir/rilpivirine (Juluca) in Europe as dual-therapy HIV switch option

Meta-analysis of TAF vs TDF in boosted vs unboosted regimens

Meta-analysis of dolutegravir in naive, experienced and switch studies

Drug cost savings from routine use of generic ARVs: safety and efficacy in practice

Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV

Bictegravir at CROI 2018: switching studies and drug resistance analyses

FDA approves ibalizumab in the US to treat multidrug HIV resistance

FDA grants tentative approval to first DTG/FTC/TAF FDC

Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)

US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)

ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART

US darunavir label updated: drug interactions and pregnancy

Doravirine FDC submitted to FDA in US: decision expected October 2018

FDA approves raltegravir for newborns

Fostemsavir in highly treatment-experienced participants: 24-week phase 3 results

D/C/F/TAF: phase 3 naive results and splitting PI-based FDC tablets

Switch study shows F/TAF non-inferior to continuing abacavir/3TC

No impact on bioavailability of D/C/F/TAF when tablet is split but TAF absorption is reduced if crushed

ABX464 nudges viral reservoir but not time to viral rebound

Long-acting ART for children is a deferred priority despite achievable dosing

Coformulated dolutegravir plus rilpivirine approved in US (Juluca)

Darunavir-based single pill FDC approved in EU (Symtuza)

Dual therapy with darunavir/r plus lamivudine as first-line ART

Dual therapy with dolutegravir plus lamivudine as first-line ART

Once-daily raltegravir: 96-week results from the ONCEMRK study

Gilead uses voucher to speed FDA review of bictegravir

HIV pipeline drugs: IAS 2017 update

Darunavir/cobicistat/FTC/TAF: 24-week interim results from phase 3 switch study

Phase 3 results with bictegravir FDC: a new integrase inhibitor combined with FTC/TAF

Doravirine/3TC/TDF compared to efavirenz/FTC/TDF as first-line ART

Continued viral suppression with long-acting cabotegravir/rilpivirine injections: 96-week LATTE-2 results

Reduced-dose darunavir is safe and effective in switch study

MK-8591: further compelling early results for both treatment and prevention

Dolutegravir outperforms lopinavir/ritonavir second-line: interim results from the DAWNING study

First dolutegravir-based FDC gets FDA tentative approval

FDA grant priority review for ibalizumab

Introduction to HIV pipeline 2017

HIV pipeline 2017: full version

HIV pipeline 2017: summary version

HIV pipeline 2017: Update from IAS Paris

Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Dolutegravir pharmacokinetics in pregnancy

High rates of of undocumented efavirenz-related side effects in Uganda

Increased risk of ART failure after low-level viraemia in a large South African cohort

Option B+ Malawi

Dolutegravir/rilpivirine submitted to EMA and FDA as oral two-drug maintenance combination

Bictegravir/FTC/TAF: new once-daily integrase-based FDC submitted to US FDA

FDA updates cobicistat and Stribild labels: interactions with systemic, inhaled, nasal and ophthalmic corticosteriods

Drop in HIV incidence in gay men: frequent testing, early ART and PrEP

Prompt/early ART: Dean Street pilot project reports 75% uptake

Other selections and webcasts

Dose reduction potential of nanoparticle ARV formulations confirmed in humans

VRC01 in HIV-exposed newborns: first results support monthly injections for those at risk through breastfeeding

Raltegravir pharmacokinetic targets met in high-risk HIV-exposed infants

Tenofovir alafenamide exposure is modestly higher in children than adults

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

Increased risk of IRIS with integrase inhibitors reported in two studies

Pharmacokinetics and full phase 2 results for bictegravir, a new integrase inhibitor

New NNRTI doravirine is non-inferior to darunavir/r in phase 3 treatment naive study

NRTI GS-9131 resurfaces at CROI 2017: in vitro sensitivity to nuke-resistant HIV

Dolutegravir exposure increases when fixed dose combination tablets are crushed

Pharmacokinetics, safety and efficacy of dolutegravir in very young children

Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Post navigation